Axsome Therapeutics, Inc. (AXSM) Covered Calls

You can sell covered calls on Axsome Therapeutics, Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for AXSM (prices last updated Mon 4:16 PM ET):

Axsome Therapeutics, Inc. (AXSM) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
164.49 +2.16 160.00 165.00 412K - 8.3
Covered Calls For Axsome Therapeutics, Inc. (AXSM)
Expiration Strike Call Bid Net Debit Return
If Flat
Annualized
Return If Flat
Mar 20 165 2.25 162.75 1.4% 42.6%
Apr 17 165 6.30 158.70 4.0% 36.5%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial


Extended Business Description

Axsome Therapeutics, Inc., a clinical stage biopharmaceutical company, is developing novel therapies for central nervous system (CNS) disorders. Its product candidate portfolio includes AXS-05, AXS-09, AXS-02, AXS-07, and AXS-06. AXS-05 is in the Phase III clinical trial in treatment resistant depression and in agitation associated with Alzheimer's disease, as well as in the Phase II clinical trial for smoking cessation. AXS-02 is also in the Phase III clinical trial in knee osteoarthritis associated with bone marrow lesions pursuant to a special protocol assessment and in chronic low back pain associated with Modic changes. AXS-07 is in Phase I clinical trial for the acute treatment of migraine. AXS-06 is also in Phase I clinical trial for the treatment of osteoarthritis and rheumatoid arthritis and for the reduction of the risk of nonsteroidal anti-inflammatory drug associated gastric ulcers. AXS-09 is a novel, oral medicine combination of esbupropion and dextromethorphan, which is in Phase I clinical trial. The company has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase II trial in smoking cessation. It has operations in the United States and Australia. The company was founded in 2012 and is based in New York, New York.

 
Top 10 Open Interest For Mar 20 Expiration     Top 5 High Yield
1.NVDA covered calls 6.QQQ covered calls   1.CTMX covered calls
2.SLV covered calls 7.EWZ covered calls   2.PATH covered calls
3.EEM covered calls 8.GLD covered calls   3.KSS covered calls
4.SPY covered calls 9.FXI covered calls   4.OWL covered calls
5.IBIT covered calls 10.KWEB covered calls   5.USO covered calls

Want more examples? |

Risk Disclosure: Trading options involves significant risk and is not suitable for all investors. The information provided on this website is for educational and informational purposes only and does not constitute financial, investment, tax, or legal advice. Nothing contained on this site is an offer to buy or sell, or a solicitation of an offer to buy or sell, any securities or financial instruments.

Covered Call Strategy Risks: While covered call writing is often considered a conservative options strategy, it is not without risk. By selling a covered call, you are limiting your potential upside profit from the underlying stock. You remain exposed to the full downside risk of owning the underlying stock. In the event of a significant decline in the stock price, the premium received may not be sufficient to offset your losses.

No Guarantee of Performance: Past performance is not indicative of future results. Any examples, calculations, or hypothetical scenarios presented on this site are for illustrative purposes only and do not guarantee future returns or outcomes. Market conditions, liquidity, and trading system failures can affect your ability to execute trades at desired prices.

You should consult with a qualified professional advisor and conduct your own due diligence before making any investment decisions. By using this website, you acknowledge that you are responsible for your own investment decisions and agree to release this site and its affiliates from any liability relating to your use of this information. See the OCC's Characteristics and Risks of Standardized Options for more info.